Tenax Therapeutics Phase

Recent news mentioning Tenax Therapeutics Phase

• 2026-08-10 — Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Appears alongside

• LEVEL
• PH-HFpEF

Browse the full archive →